Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 5, 2007, Pages 971-979

  Castoldi, Elisabetta ^a   Simioni, P ^b   Tormene, D ^b   Thomassen, M C L G D ^a   Spiezia, L ^b   Gavasso, S ^b   Rosing, J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

APC resistance; High prothrombin levels; PT A19911G; PT G20210A; Thrombin generation; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; PROTEIN S; PROTHROMBIN; THROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEMATOLOGIC DISEASE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; HYPERPROTHROMBINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; FEMALE; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTHROMBIN; THROMBIN;

EID: 34247877798     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02448.x     Document Type: Article

References (38)

1. Dahlbäck B. Blood coagulation. Lancet 2000; 355: 1627-32.
2. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
3. Curvers J, Thomassen MC, Rimmer J, Hamulyák K, van der Meer J, Tans G, Preston FE, Rosing J. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost 2002; 88: 5-11.
4. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
6. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-8.
7. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE. Increased efficiency of mRNA 3′ end formation: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28: 389-92.
8. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thromb Haemost 2004; 2: 119-27.
9. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Frede U, Hentze MW, Kulozik AE. The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood 2004; 104: 428-35.
10. Carter AM, Sachchithananthan M, Stasinopoulos S, Maurer F, Medcalf RL. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost 2002; 87: 846-53.
11. Pollak ES, Lam HS, Russell JE. The G20210A mutation does not affect the stability of prothrombin mRNA in vivo. Blood 2002; 100: 359-62.
12. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001; 85: 1066-70.
13. Pérez-Ceballos E, Corral J, Alberca I, Vaya A, Llamas P, Montes R, Gonzalez-Conejero R, Vicente V. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis. Br J Haematol 2002; 118: 610-4.
14. Martinelli I, Battaglioli T, Tosetto A, Legnani C, Sottile L, Ghiotto R, Mannucci P. Prothrombin 19911 A > G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 2006; 4: 2582-6.
15. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJ. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: Results of the MEGA study, a large population-based case-control study. J Thromb Haemost 2006; 4: 2587-92.
16. von Ahsen N, Oellerich M. The intronic prothrombin 19911A > G polymorphism influences splicing efficiency and modulates effects of the 20210G > A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood 2004; 103: 586-93.
17. Kyrle PA, Mannhalter C, Béguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
18. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood 2003; 101: 3008-13.
19. Koenen RR, Tans G, van Oerle R, Hamulyák K, Rosing J, Hackeng TM. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood 2003; 102: 1686-92.
20. SeréKM, Rosing J, Hackeng TM. Inhibition of thrombin generation by protein S at low procoagulant stimuli: Implications for maintenance of the hemostatic balance. Blood 2004; 104: 3624-30.
21. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-61.
22. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999; 94: 3839-46.
23. Mitchell CA, Jane SM, Salem HH. Inhibition of the anticoagulant activity of protein S by prothrombin. J Clin Invest 1988; 82: 2142-7.
24. Tripodi A, Chantarangkul V, Mannucci PM. Hyperprothrombinemia may result in acquired activated protein C reistance. Blood 2000; 96: 3295-6.
25. Castaman G, Tosetto A, Simioni M, Ruggeri M, Madeo D, Rodeghiero F. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb Haemost 2001; 86: 804-8.
26. de Visser MC, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AE, Sandset PM, Rosendaal FR, Bertina RM. Determinants of the APTT-based and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-94.
27. Brugge JM, Tans G, Rosing J, Castoldi E. Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels. Thromb Haemost 2006; 95: 236-42.
28. Binetti BM, Rotunno C, Tripodi A, Asti D, Semeraro F, Semeraro N, Colucci M. Hyperprothrombinaemia-induced APC resistance: Differential influence on fibrin formation and fibrinolysis. Thromb Haemost 2006; 95: 606-11.
29. Rosendaal FR, Bovill EG. Heritability of clotting factors and the revival of the prothrombotic state. Lancet 2002; 359: 638-9.
30. Souto JC, Almasy L, Blangero J, Stone W, Borrell M, Urrutia T, Mateo J, Fontcuberta J. Genetic regulation of plasma levels of vitamin K-dependent proteins involved in hematostatis: Results from the GAIT Project. Genetic Analysis of Idiopathic Thrombophilia. Thromb Haemost 2001; 85: 88-92.
31. van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and d-dimer levels in healthy individuals. J Thromb Haemost 2003; 1: 516-22.
32. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Béguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
33. Thomassen MCLG, Castoldi E, Tans G, Magdeleyns EJ, Delaunoit C, Debusscher L, Van Assche KJ, Rosing J. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Haematologica 2003; 88: 1150-6.
34. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296: 397-402.
35. Brandts A, van Hylckama Vlieg A, Rosing J, Baglin TP, Rosendaal FR. The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C. J Thromb Haemost 2007; 5: 416-8.
36. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003; 122: 465-70.
37. Hézard N, Bouaziz-Borgi L, Remy MG, Nguyen P. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52: 665-70.
38. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 2002; 71: 285-90.